HomeStructural heart diseaseValvular Aortic valve

Valvular Aortic valve

View Category

Antiplatelet

Dual Antiplatelet Therapy and TAVR: Obsolete Guidelines

The current guidelines recommend dual antiplatelet therapy (DAPT) 3 to 6 months after transcatheter aortic valve replacement...
solaci -
Learn More
Institutional News

29/04 | Webinar SOLACI – TAVI TALKS: Why Hemodynamics Really Matters

solaci -
Learn More
Structural heart disease

Cerebral Protection Devices during TAVR in the Daily Practice

The theory behind the use of cerebral protection devices during TAVR is good, but hard to test....
solaci -
Learn More
Structural heart disease

TAVR vs. the Least Invasive Surgically Implanted Valve

Rapid-deployment surgically implanted valves are designed to make a surgeons’ job faster and easier, compared with conventional...
solaci -
Learn More
Structural heart disease

SCOPE I: Acurate NEO vs Sapien 3, no non-inferiority at one year?

The randomized controlled study SCOPE 1 failed to show significant differences at one year between the self-expandable...
solaci -
Learn More
Structural heart disease

Surgeons’ Claim on Low-Risk Patients with Aortic Stenosis

Recent randomized trials including low-risk patients showed positive results for transcatheter aortic valve replacement (TAVR) compared with...
solaci -
Learn More
Structural heart disease

High Deployment: Also Trending with Balloon Expandable Valves

Conventional implantation of balloon expandable SAPIEN-3 results in a final 70:30 or 80:20 ratio of the valve...
solaci -
Learn More
Structural heart disease

Cusp Overlap for Higher CoreValve Implantation

Implant depth greater than the length of the membranous septum is an independent predictor of permanent pacemaker...
solaci -
Learn More